Trial Profile
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary) ; Carbamazepine
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB
- 01 Nov 2023 Results of Exploratory post hoc analysis evaluating the efficacy and tolerability of lacosamide (LCM) versus controlled release carbamazepine (CBZ-CR) monotherapy in adults with newly diagnosed , published in the Seizure: European Journal of Epilepsy
- 17 Nov 2020 Results (n=271) of post-hoc analysis assessing serologic data from a randomized monotherapy trial comparing the controlled-release formulation of CBZ with LCM for the treatment of new-onset focal epilepsy, published in the Epilepsia.
- 12 Nov 2019 Results of post hoc analyses of pooled long term safety and efficacy data from (NCT01465997 and NCT01243177) published in the Epilepsia published in the Epilepsia